No Data
Relay Therapeutics Is Maintained at Overweight by Barclays
Barclays Maintains Relay Therapeutics(RLAY.US) With Buy Rating, Cuts Target Price to $14
We're Not Very Worried About Relay Therapeutics' (NASDAQ:RLAY) Cash Burn Rate
Relay Therapeutics Is Maintained at Market Outperform by JMP Securities
Relay Therapeutics Price Target Cut to $21.00/Share From $24.00 by JMP Securities
Express News | JMP Securities Maintains Market Outperform on Relay Therapeutics, Lowers Price Target to $21